Lymphocyte Subsets in Pamidronate-induced Lymphopenia

Lioté, Frédéric; Boval-Boizard, B.; Fritz, Paul J.; Kuntz, D

doi:10.1093/rheumatology/34.10.993

Cited by 12 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, ZA can inhibit the activation of monocyte-derived dendritic cells (21). The immune effects of ZA are further documented by the clinical inflammatory syndrome that occurs in many patients upon first doses and is associated with a transient decrease in the number of lymphocytes circulating in peripheral blood (22,23). Through indirect mechanisms, ZA was found to enhance N� cell effector functions (24), supporting the combination of the two strategies.…”

Section: Introductionmentioning

confidence: 92%

Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells

et al. 2013

View full text Add to dashboard Cite

Abstract. Disseminated Ewing sarcoma remains a fatal disease despite advanced multimodal treatment regimens. Immunotherapies as well as novel drugs and biologicals are currently being explored to eliminate minimal residual disease after conventional therapy thereby rescuing patients at a high risk for relapse. Insights into the interactions between novel therapies provide the basis for the development of effective combination strategies. We investigated the effects of the aminobisphosphonate zoledronic acid (ZA) on the in vitro expansion of human natural killer (N�) cells and their cytonatural killer (N�) cells and their cyto-N�) cells and their cytolytic activity against Ewing sarcoma cells. ZA significantly impaired the in vitro expansion of activated N� cells from both healthy donors and Ewing sarcoma patients in a dosedependent manner. Expression of differentiation markers and activating receptors was unaffected by the drug. Activated N� cells from both healthy donors and patients had potent degranulation responses to Ewing sarcoma cells. In the presence of ZA at concentrations reflecting pharmaceutical serum levels, the in vitro antitumor activity of N� cells from Ewing sarcoma patients was significantly impaired. We conclude that ZA can impede in vitro N� cell expansion and cytolytic N� cell responses to Ewing sarcoma. These observations raise caution against the combination of adoptive N� cell transfer with ZA maintenance therapy in Ewing sarcoma. Future studies aim to identify potentiating interactions of novel drugs with cellular therapies.

show abstract

Section: Introductionmentioning

confidence: 92%

Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Thus, some patients who receive an amino-bisphosphonate intravenously for the first time show a transient pyrexia of 1-2 degrees C, sometimes more, accompanied by flu-like symptoms (111,213). This episode is accompanied by a decrease in peripheral lymphocytes, especially the CD3ϩ T cells (214), an increase in C-reactive protein, and (217)(218)(219)(220)(221). The effect on the joints is especially pronounced when the bisphosphonates are encapsulated in liposomes (222,223).…”

Section: February 1998 Bisphosphonates: Mechanisms Of Action 89mentioning

confidence: 99%

Bisphosphonates: Mechanisms of Action

1998

View full text Add to dashboard Cite

“…A transient T-helper lymphopenia has also been observed within 24 h, with reductions of up to 50% in CD4-positive lymphocyte levels in peripheral blood [2]. Inflammatory reactions following drug administration appear to be the result of increased cytokine release from macrophages and monocytes.…”

Section: Introductionmentioning

confidence: 99%

Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis

et al. 2009

View full text Add to dashboard Cite

A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy. The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure. After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis. Urinary volume and serum creatinine levels recovered to the normal range, with urinary protein disappearing completely within 40 days. This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.

show abstract

Lymphocyte Subsets in Pamidronate-induced Lymphopenia

Cited by 12 publications

References 0 publications

Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells

Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells

Bisphosphonates: Mechanisms of Action

Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis

Contact Info

Product

Resources

About